The Latest Cardiac and Vascular News
– Revenue in the fourth quarter of 2021 increased 8 percent, driven by volume growth of 11 percent. Excluding COVID-19 antibodies, fourth-quarter 2021 revenue grew 6 percent. – Full-year 2021 revenue increased 15 percent, driven by volume growth of 16 percent. Excluding COVID-19 antibodies, full-year 2021 revenue grew 10 percent. […]
SUNNYVALE, Calif.–(BUSINESS WIRE)–BioCardia®, Inc. (Nasdaq: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for the CardiAMP® Cell Therapy System for the treatment of heart failure. It is believed […]
Ontario, Canada, Feb. 03, 2022 (GLOBE NEWSWIRE) — Kitchener, ON – February 3, 2022– Vena Medical is excited to announce the first Health Canada Medical Device License for their new product, the Vena Balloon Distal Access Catheter™[1] (BDAC). The Vena BDAC™ combines the balloon guide catheters and distal access catheters that are currently […]
AnaCardio exercises option to license a program in heart failure from Helsinn Lugano, Switzerland and Stockholm, Sweden, February 3, 2022 – Helsinn Group (“Helsinn”), a fully integrated, global biopharma company with a diversified pipeline of innovative oncology assets and strong track-record of commercial execution, and AnaCardio, a clinical stage biopharmaceutical company developing novel drugs to treat heart failure, are pleased to announce that AnaCardio has […]
LIVMOR to Develop HeartBeam Branded Version of the FDA Registered LIVMOR Halo+ Portal SANTA CLARA, Calif.–(BUSINESS WIRE)–HeartBeam, Inc. (NASDAQ: BEAT), a developmental stage digital healthcare company with a proprietary ECG telemedicine technology for heart attack detection, today announced it has signed a partnership agreement with LIVMOR Inc., a digital health […]
Phase 2a clinical trial evaluating REG-101 for PAD expected to initiate second half of 2022 ROCKVILLE, Md.–(BUSINESS WIRE)–Regio Biosciences (Regio), a Hibiscus BioVentures company, announced today it has entered into an exclusive license agreement with AstraZeneca to further develop REG-101, a novel therapeutic acting on reverse cholesterol transport (RCT). Regio expects to initiate a […]
Increasing Low End of Guidance: $1,025 Million – $1,030 Million, up 21% – 22% DANVERS, Mass.–(BUSINESS WIRE)–ABIOMED, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced financial results for the quarter ended December 31, 2021. Q3 financial summary and operational highlights: Revenue for the quarter totaled […]
Fourth-Quarter and Full-Year Results Reflect Continued Strong Business Momentum and Operational Strength Fourth-Quarter 2021 Worldwide Sales From Continuing Operations Were $13.5 Billion, an Increase of 24% From Fourth-Quarter 2020; Excluding the Impact From Foreign Exchange, Sales Grew 23%; Includes $952 Million of Molnupiravir Sales Fourth-Quarter 2021 GAAP EPS From Continuing […]
EDEN PRAIRIE, Minn.–(BUSINESS WIRE)–Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2022 first quarter ended December 31, 2021. Summary of First Quarter and Recent Highlights Revenue of $23.0 million, an increase of 3% […]
Clinicians indicate both Holter and MCT usage expected to grow in 2022 despite their differences CAMPBELL, Calif., Feb. 2, 2022 /PRNewswire/ — Vivalink, a leading provider of digital healthcare solutions, today announced the results of a company survey focused on clinicians’ use of Holter monitors versus mobile cardiac telemetry (MCT). The survey results […]
